Q3 2025 Ascelia Pharma AB Earnings Call Transcript
Key Points
- Ascelia Pharma AB (FRA:7ZA) submitted a New Drug Application (NDA) for Orviglance to the FDA in Q3, marking a significant regulatory milestone.
- The company successfully raised SEK30 million and converted outstanding convertibles, resulting in a strengthened and clean balance sheet.
- Orviglance addresses a well-defined unmet need for liver imaging in cancer patients with impaired kidney function, targeting an $800 million US market.
- The company has completed all clinical development for Orviglance, including a strong Phase 3 study, and established commercial-scale manufacturing.
- Ascelia Pharma AB is actively seeking a partner for the commercialization of Orviglance, leveraging existing commercial infrastructure for a focused launch.
- The company reported an operating loss of SEK15 million in Q3, although this was lower than the previous quarter.
- There is uncertainty regarding the timeline for securing a commercialization partner, which could impact the launch strategy for Orviglance.
- The market for Orviglance is highly specialized, targeting a small patient population, which may limit broader market penetration.
- Potential competition from other manganese-based imaging agents in development could pose a threat to Orviglance's market position.
- The company faces ongoing regulatory risks and must await the FDA's decision, expected by early July next year, which could affect future plans.
Welcome to today's presentation where we have the pleasure to present Ascelia Pharma. So it was today's presentation, we are joined by Julie Brogren, Deputy CEO of the company. Today, of course, the Q3 announcement yesterday is that the occasion but as always in a biotech, of course, more focused on the regulatory and milestones on the pipeline, achieved during the quarter and of course, a short reminder of the case into (Inaudible).
As always, ask questions in the box down below. Do it in Danish if you feel for it. I will TRY and translate to the best of my ability. But for now, I'll hand the call over to you Julie.
Yes
Thank you, Magnus. It's good to be here. So, Ascelia Pharma, I'll be making some forward-looking statements. So please, pay attention to this.
We work, in orphan oncology. We identify, develop, and commercialize all, novel drugs that can help people with different, rare cancer
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
